Fenbendazole works by binding to a structural protein called tubulin, which both parasites and cancer cells need to build their internal scaffolding. In worms, this binding collapses the microtubule network that the parasite depends on for cell division, nutrient transport, and survival. In cancer cells grown in the lab, the same tubulin-targeting action disrupts cell division and triggers several additional stress pathways. The overlap in mechanism is why a veterinary dewormer has attracted so much interest as a potential anti-cancer compound, but the story is far more complicated than the shared target suggests.
How Fenbendazole Kills Parasites
Fenbendazole belongs to the benzimidazole family of drugs, which have been used to treat parasitic worm infections in animals for decades. The drug’s primary target is beta-tubulin, a protein that parasites use to construct microtubules. Microtubules are tiny tube-shaped structures inside cells that serve as both a skeletal framework and a transport highway. When fenbendazole binds to parasite tubulin, it prevents the protein from assembling into functional microtubules. Without that scaffolding, the worm’s cells can’t divide, can’t move nutrients around, and ultimately die.
Tubulin binding isn’t the only thing going on. Research on the whipworm Trichuris globulosa showed that fenbendazole markedly inhibited glucose uptake at concentrations low enough that the parasites were still physically moving. In other words, the drug was already starving the worms of their energy source before it visibly paralyzed them.
1Veterinary Parasitology. Effect of thiabendazole and fenbendazole on glucose uptake and carbohydrate metabolism in trichuris globulosaThis two-pronged attack, disrupting both the structural framework and the energy supply, is what makes benzimidazoles so effective against a wide range of intestinal worms, roundworms, and lungworms in livestock, pets, and laboratory animals.
Why the Same Drug Affects Cancer Cells
Tubulin isn’t unique to parasites. Human cells also rely on microtubules, especially during cell division when the chromosomes need to be pulled apart by a structure called the mitotic spindle. Several established chemotherapy drugs, including the taxanes and vinca alkaloids, work by targeting microtubules. Fenbendazole does something similar, though it’s considerably weaker at disrupting mammalian tubulin than drugs designed specifically for that purpose.
A widely cited 2018 study on human non-small-cell lung cancer cells found that fenbendazole showed moderate affinity for mammalian tubulin and killed cancer cells at micromolar concentrations. The researchers compared its microtubule-disrupting strength to colchicine, a well-known tubulin poison, and found the effect was much milder. Colchicine nearly eliminated the polymerized form of tubulin in treated cells, while fenbendazole caused only a modest decrease.
2PubMed Central. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathwaysThat moderate strength might actually be relevant to the drug’s appeal. Potent microtubule-disrupting agents like colchicine are too toxic for routine cancer treatment, because they destroy the microtubules in healthy cells just as readily. Fenbendazole’s relatively gentle tubulin-binding activity has led some researchers to wonder whether it could interfere with cancer cells while doing less collateral damage to normal tissue. Lab experiments on canine brain tumor cells, for instance, showed that fenbendazole disrupted tubulin in the cancer cells at concentrations that had no significant effect on normal fibroblasts.
3Wiley Online Library. In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cellsAdditional Anti-Cancer Pathways Identified in Lab Studies
If microtubule disruption were the whole story, fenbendazole wouldn’t attract nearly as much attention. The drug appears to trigger several other cellular stress responses in cancer cells, at least in laboratory settings. A review of benzimidazole anthelmintics catalogued the observed anti-cancer activities across multiple studies: disruption of microtubule polymerization, induction of programmed cell death (apoptosis), cell cycle arrest at the G2/M phase, anti-angiogenesis (blocking the growth of new blood vessels that tumors need), and blockage of glucose transport.
4PubMed Central. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing DrugsThe cell cycle arrest finding has been replicated in several cell types. When canine melanoma cells were treated with fenbendazole, researchers observed that cells became stuck at the G2/M checkpoint, the stage just before cell division, and many underwent “mitotic slippage,” where the cell exits mitosis without actually dividing properly. Imaging showed microtubule defects along with cells that had abnormally large or multiple nuclei.
5PubMed Central. G2/M arrest and mitotic slippage induced by fenbendazole in canine melanoma cellsSimilarly, work on colorectal cancer cells, including a line resistant to the chemotherapy drug 5-fluorouracil, showed dose-dependent anti-proliferative effects. Fenbendazole significantly induced apoptosis and cell cycle arrest at G2/M in both the regular and drug-resistant cancer cells.
6Korean Journal of Physiology & Pharmacology. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cellsThat last point about drug-resistant cells is what makes some researchers particularly interested. When cancer cells develop resistance to a standard chemotherapy agent, they sometimes remain vulnerable to a drug that works through a different mechanism. Fenbendazole’s multi-target activity, hitting microtubules, glucose transport, and apoptosis pathways simultaneously, could theoretically offer ways around certain resistance mechanisms. But all of this has been shown in cell cultures, not in patients.
The Gap Between Lab Results and Living Animals
Cell culture experiments are the earliest stage of testing, and many compounds that kill cancer cells in a dish fail completely when given to a living organism. One of the most sobering results in the fenbendazole literature comes from a study that tested it as a dietary supplement in mice with mammary tumors. Mice were fed a diet containing 150 parts per million of fenbendazole before and during tumor growth. The result: fenbendazole did not alter tumor growth, invasion, or metastasis.
7PubMed Central. Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studiesA companion experiment from the same research group, however, produced a puzzling twist. When fenbendazole was given alongside supplementary vitamins, significant tumor growth inhibition was observed. Neither the vitamins alone nor fenbendazole alone had any effect on tumor growth. The combination, for reasons the researchers stated were unknown, produced a synergistic result.
8PubMed Central. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitaminsThis finding has never been fully explained, and the specific vitamins, doses, and mechanisms involved haven’t been replicated in a controlled way that would allow anyone to draw practical conclusions. It does, however, illustrate why the fenbendazole story resists simple summarization. The drug alone didn’t work in a living animal. The drug combined with vitamins did. Nobody knows why. That kind of result fuels both legitimate scientific curiosity and unwarranted internet hype in roughly equal measure.
The Bioavailability Problem
One major reason fenbendazole might fail in whole animals despite working in cell cultures is bioavailability: how much of the drug actually reaches the bloodstream after being swallowed. Fenbendazole is poorly soluble in water, and in most species studied, only a fraction of an oral dose is absorbed.
In pigs, oral bioavailability was about 27%, with peak blood levels of just 0.07 micrograms per milliliter reached roughly four hours after dosing.
9PubMed. Pharmacokinetics of fenbendazole following intravenous and oral administration to pigsIn alpacas, the picture was even less encouraging: systemic bioavailability averaged around 16%, with enormous individual variation ranging from as low as 1% to as high as 41%. Peak blood concentrations were just 0.13 micrograms per milliliter, reached about ten hours after dosing.
10PubMed Central. Plasma concentrations of fenbendazole (FBZ) and oxfendazole in alpacas (Lama pacos) after single intravenous and oral dosing of FBZFor killing intestinal parasites, low systemic absorption isn’t necessarily a problem; the drug encounters the worms directly in the gut. But for reaching a tumor in the lung, brain, or ovary, you need meaningful blood concentrations, and the numbers from animal pharmacokinetic studies suggest that standard oral doses may not deliver enough drug to the tumor site. This disconnect between the micromolar concentrations that kill cancer cells in a dish and the sub-micromolar levels actually achieved in the bloodstream is a fundamental challenge.
What Happens to Fenbendazole in the Body
Once absorbed, fenbendazole doesn’t simply circulate and then leave. The liver converts it into several metabolites, and at least one of them, oxfendazole (the sulfoxide form), is itself an active antiparasitic agent used in its own right. A comparative study of liver metabolism across nine species, from cattle and sheep to chickens, rabbits, and catfish, found that all species produced oxfendazole. Most also produced a hydroxylated metabolite and a further-oxidized sulfone form, though the rates varied dramatically between species.
11PubMed. The oxidative metabolism of fenbendazole: a comparative studyThis metabolic variability matters for two reasons. First, the anti-cancer activity observed in lab studies was tested with fenbendazole itself, but in a living body, the drug is rapidly converted into metabolites whose anti-tumor properties may differ. Second, species-specific differences in metabolism mean that results from mice, pigs, or alpacas don’t translate directly to humans. Human pharmacokinetic data for fenbendazole is extremely limited, since the drug has never been formally developed for human use.
Drug Resistance in Parasites
While fenbendazole remains effective against many parasitic worms, resistance has become a serious concern in veterinary medicine. The mechanism of resistance is elegant in its simplicity: mutations in the beta-tubulin gene change the shape of the protein just enough that fenbendazole can no longer bind effectively, while the tubulin still functions normally for the parasite.
Researchers have identified specific mutations at several positions on the beta-tubulin gene that confer resistance. A study testing newly identified parasitic nematode beta-tubulin alleles found that all tested variants showed significant increases in resistance compared to susceptible laboratory strains.
12PubMed Central. Newly identified parasitic nematode beta-tubulin alleles confer resistance to benzimidazolesThe problem is particularly acute in hookworms infecting domestic dogs in the United States. A molecular survey found that the F167Y resistance mutation was present in roughly half of the individual hookworm samples tested, and in many of those samples, the resistant allele was at a frequency above 50%, meaning it had become the dominant version in those worm populations.
13PLoS Pathogens. Molecular evidence of widespread benzimidazole drug resistance in Ancylostoma caninum from domestic dogs throughout the USA and discovery of a novel β-tubulin benzimidazole resistance mutationThis widespread resistance in parasites provides an interesting contrast to the cancer discussion. In worms, resistance emerges through straightforward genetic selection: use the drug long enough, and the worms with tubulin mutations survive and reproduce. Whether cancer cells could develop analogous resistance to fenbendazole’s tubulin-binding activity is an open question, though the multi-target nature of the drug’s anti-cancer effects might make single-point resistance less likely than it is in parasites, where tubulin binding is the primary kill mechanism.
Self-Medication and Safety Concerns
Fenbendazole gained widespread public attention after a man named Joe Tippens publicized his claim that the drug helped cure his cancer, a story that went viral on social media beginning around 2019. Since then, a growing number of cancer patients have turned to self-administering veterinary fenbendazole formulations, typically without medical supervision.
A 2025 case series in a medical journal described three patients who independently chose to take fenbendazole after exhausting or refusing standard cancer therapies. The authors emphasized that in all three cases, the decision was patient-initiated, without medical recommendation, and occurred outside regulated clinical settings. They described the trend as concerning, noting that without regulatory oversight, appropriate dosing, quality control, and safety monitoring are inadequate.
14PubMed Central. Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three PatientsOne concrete risk that has surfaced is liver injury. A case report documented a patient who developed liver toxicity while self-administering fenbendazole at high doses alongside immunotherapy. Distinguishing fenbendazole-induced liver damage from immunotherapy-related hepatitis required careful investigation, illustrating the diagnostic confusion that can arise when patients combine unapproved treatments with standard cancer therapy.
15PubMed Central. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis – the importance of structured causality assessmentVeterinary formulations of fenbendazole are manufactured to standards appropriate for animals, not humans. The inactive ingredients, concentrations, and purity standards differ from what would be required for a human pharmaceutical. People who purchase animal dewormer pastes or granules are using a product that was never designed for human consumption, at doses that have no established safety profile in humans.
Efforts to Improve Drug Delivery
Recognizing the bioavailability problem, some researchers have begun experimenting with advanced formulations to get more fenbendazole into the bloodstream and, ideally, into tumors. One approach involves encapsulating the drug in tiny biodegradable polymer nanoparticles. A study on ovarian cancer used PLGA nanoparticles loaded with fenbendazole, specifically designed to enhance the drug’s water solubility and absorption.
16PubMed Central. Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancerThis kind of nanoparticle delivery system is well-established in pharmaceutical research and has been used with various poorly soluble drugs. The idea is straightforward: wrap the drug in a tiny shell that dissolves slowly in the body, allowing more of the compound to reach the target tissue. Whether this approach could ever make fenbendazole viable as a human cancer therapy would require extensive testing, first in animals and then in clinical trials.
Where Clinical Evidence Stands
As of mid-2025, no completed randomized clinical trial has tested fenbendazole as a cancer treatment in humans. The entire body of anti-cancer evidence consists of cell culture experiments, a handful of animal studies with mixed results, and scattered case reports of patients who self-administered the drug. The review literature has described fenbendazole’s anti-cancer biological activities as “promising” in experimental studies, while consistently noting the absence of human clinical data.
2PubMed Central. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathwaysThe gap between cell-culture results and a working cancer drug is enormous. Thousands of compounds kill cancer cells in a dish. Only a small fraction work in animal models, and only a small fraction of those survive human clinical trials. Fenbendazole has shown enough mechanistic interest to justify further investigation, but it has not even begun the formal process that would determine whether it actually helps cancer patients. The mechanisms are real. The multi-pathway activity is genuinely interesting. The clinical proof is entirely absent.
For parasites, by contrast, fenbendazole’s track record is long and well-documented. It has been used globally in veterinary medicine since the 1970s and remains a standard treatment for gastrointestinal nematodes, lungworms, and certain tapeworm species across a wide range of animal hosts. The drug’s safety profile in animals is well-characterized, its dosing protocols are established, and its limitations, primarily the growing problem of resistance, are understood. The veterinary success story is not in question. What remains to be seen is whether any version of that success can be meaningfully translated to oncology.